For over a decade Sandoz, a Novartis division, has been the pioneer and global leader in biosimilars. This year marks ten years since Sandoz launched the world’s first biosimilar, Omnitrope®, in the EU, giving rise to the era of affordable biologics that have helped to treat millions of patients and liberate billions of dollars in healthcare costs. We continue to invest in research and development into these life changing medicines.
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
July 13, 2016
Sandoz, a Novartis division and leader in biosimilars, announced today that the US Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of its proposed biosimilar etanercept...
Sandoz has world-class expertise in the development, manufacture and delivery of biosimilar medicines to help patients and the healthcare community.Read more
Sandoz is dedicated to improving patients’ lives and liberating healthcare resources, by increasing access to high-quality, affordable biosimilars.Read more